Related references
Note: Only part of the references are listed.Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex
Shenyan Gu et al.
SCIENCE (2012)
Structural Basis of TLR5-Flagellin Recognition and Signaling
Sung-il Yoon et al.
SCIENCE (2012)
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial
Francisco Cruz et al.
EUROPEAN UROLOGY (2011)
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies
M. Zouhair Atassi et al.
IMMUNOBIOLOGY (2011)
MODULATION OF BOTULINUM TOXIN-INDUCED CHANGES IN NEUROMUSCULAR FUNCTION WITH ANTIBODIES DIRECTED AGAINST RECOMBINANT POLYPEPTIDES OR FRAGMENTS
S. G. Joshi et al.
NEUROSCIENCE (2011)
Efficacy and Tolerability of Botulinum Toxin Type A in Patients with Neurogenic Detrusor Overactivity and Without Concomitant Anticholinergic Therapy: Comparison of Two Doses
Philippe Grise et al.
EUROPEAN UROLOGY (2010)
Flagellin as an Adjuvant: Cellular Mechanisms and Potential
Steven B. Mizel et al.
JOURNAL OF IMMUNOLOGY (2010)
Meta-Analysis of Neutralizing Antibody Conversion with OnabotulinumtoxinA (BOTOX®) Across Multiple Indications
Markus Naumann et al.
MOVEMENT DISORDERS (2010)
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia
Daniel Truong et al.
PARKINSONISM & RELATED DISORDERS (2010)
Long-term Safety and Efficacy of a New Botulinum Toxin Type A in Treating Glabellar Lines
Ronald Moy et al.
ARCHIVES OF FACIAL PLASTIC SURGERY (2009)
Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study
Joachim Grosse et al.
BJU INTERNATIONAL (2009)
Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?
Oliver Lange et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Editorial Response Letter to Mander et al
Terrence Hunt et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Efficacy and Safety of Botulinum Neurotoxin NT 201 in Poststroke Upper Limb Spasticity
Petr Kanovsky et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Xeomin® in the treatment of cervical dystonia
R. Benecke
EUROPEAN JOURNAL OF NEUROLOGY (2009)
An open-label, randomized, 64-week study repeating 10-and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects
Makoto Kawashima et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2009)
Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity
Kerstin Mueller et al.
JOURNAL OF NEURAL TRANSMISSION (2009)
Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: Interim analysis from an open-label extension study
Gary D. Monheit et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins
Roshan Kukreja et al.
TOXICON (2009)
An Evaluation of Neutralizing Antibody Induction During Treatment of Glabellar Lines with a New US Formulation of Botulinum Neurotoxin Type A
Ira Lawrence et al.
AESTHETIC SURGERY JOURNAL (2009)
Biosimilars: Policy, clinical, and regulatory considerations
Scott Gottlieb
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients
Elie P. Elovic et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2008)
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment
M. Zouhair Atassi et al.
MOLECULAR IMMUNOLOGY (2008)
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
Mitchell F. Brin et al.
MOVEMENT DISORDERS (2008)
Subunit Stoichiometry of the Clostridium botulinum Type A Neurotoxin Complex Determined Using Denaturing Capillary Electrophoresis
Michael A. Lietzow et al.
PROTEIN JOURNAL (2008)
Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E
Roshan V. Kukreja et al.
BIOCHEMISTRY (2007)
Botulinum toxin type a in refractory chronic migraine
Carla Menezes et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2007)
Stability of the Clostridium botulinum type a neurotoxin complex:: An empirical phase diagram based approach
Duane T. Brandau et al.
MOLECULAR PHARMACEUTICS (2007)
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: A pooled-data analysis of three clinical trials
Stuart A. Yablon et al.
CLINICAL THERAPEUTICS (2007)
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
Behzod Z. Dolimbek et al.
MOLECULAR IMMUNOLOGY (2007)
The protein load of therapeutic botulinum toxins
A. Pickett et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Botulinum neurotoxin vaccines: Past, present, and future
Leonard A. Smith et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2007)
Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study
Ingrid Ehren et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2007)
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
J. Jankovic et al.
NEUROLOGY (2006)
Clinical use of non-A botulinum toxins: Botulinum toxin type B
Dirk Dressler et al.
NEUROTOXICITY RESEARCH (2006)
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
P Roggenkämper et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Immunological aspects of Botox®, Dysport® and Myobloc™/NeuroBloc®
D Dressler et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Efficacy and safety of repeated doses of botulinum toxin type B in type a resistant and responsive cervical dystonia
SA Factor et al.
MOVEMENT DISORDERS (2005)
Botulinum toxin type B de novo therapy of cervical dystonia - Frequency of antibody induced therapy failure
D Dressler et al.
JOURNAL OF NEUROLOGY (2005)
Long-term botulinum toxin efficacy, safety, and immunogenicity
NI Mejia et al.
MOVEMENT DISORDERS (2005)
Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX (R)) for cervical dystonia
A Brashear et al.
ADVANCES IN THERAPY (2005)
Phase I comparability of recombinant human albumin and human serum albumin
D Bosse et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Basic immunological aspects of botulinum toxin therapy
MZ Atassi
MOVEMENT DISORDERS (2004)
Long-term follow-up of cervical dystonia patients treated with botulinum toxin A
P Haussermann et al.
MOVEMENT DISORDERS (2004)
Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke
MF Gordon et al.
NEUROLOGY (2004)
The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles
AMO Bakheit et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Botulinum toxin type B in upper-limb poststroke spasticity: A double-blind, placebo-controlled trial
A Brashear et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2004)
Botulinum toxin type B (Myobloc((R))): Pharmacology and biochemistry
JE Callaway
CLINICS IN DERMATOLOGY (2004)
Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure
D Dressler et al.
JOURNAL OF NEUROLOGY (2003)
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia
J Jankovic et al.
NEUROLOGY (2003)
Therapeutic use of botulinum toxins: Background and history
PE Setler
CLINICAL JOURNAL OF PAIN (2002)
Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period
GYR Hsiung et al.
MOVEMENT DISORDERS (2002)
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke
A Brashear et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Antibody-induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses?
D Dressler et al.
EUROPEAN NEUROLOGY (2002)
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
KR Aoki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2001)
Botulinum A toxin: Dysport improvement of biological availability
H Bigalke et al.
EXPERIMENTAL NEUROLOGY (2001)
The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans
D Dressler et al.
JOURNAL OF NEUROLOGY (2000)
Share Paper
